BCAX vs XYL · $1.51B cap vs P/E 27, rev $4.46B
Bicara Therapeutics Inc. Common Stock (BCAX) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
BCAX does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
BCAX currently screens at market cap $1.51B. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the BCAX and XYL stock pages for the full models.
Not investment advice.